Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...
The plugin uses the language selected in your IDE preferences. If it's a non-IDE language, select in in the plugin menu. Supported are: bg, bs, cs, da, de, el, en, es ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results